Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma
Stopped Due to inadequate funding. This trial may open as a new clinical trial at a later date, pending drug approval.
Conditions
- BCLC Stage B Hepatocellular Carcinoma
- BCLC Stage C Hepatocellular Carcinoma
- Locally Advanced Hepatocellular Carcinoma
- Recurrent Hepatocellular Carcinoma
- Unresectable Hepatocellular Carcinoma
Interventions
- BIOLOGICAL: Atezolizumab
- PROCEDURE: Biopsy
- DRUG: Cabozantinib S-malate
- RADIATION: Yttrium Y 90 Glass Microspheres
Sponsor
OHSU Knight Cancer Institute
Collaborators